Biogen's soft guidance and a decline in sales at MS portfolio weigh

Dow Jones

Feb 12, 2025

MW Biogen's soft guidance and a decline in sales at MS portfolio weigh

Biogen Inc.'s stock $(BIIB)$ fell 0.6% early Wednesday, after the biotech beat fourth-quarter earnings estimates but offered guidance that lagged consensus.

Cambridge, Mass.-based Biogen had per-share earnings of $1.83 for the quarter, up from $1.71 a year ago. Adjusted for one-time items, EPS came to $3.44, ahead of the $3.35 FactSet consensus.

Revenue rose 3% to $2.455 billion and was also ahead of the $2.408 billion FactSet consensus.

Sales of the company's Alzheimer's disease treatment Leqembi came to about $87 million, ahead of the $67 million FactSet consensus. But sales of the core multiple sclerosis portfolio fell 7% to $1.070 billion.

The company is now expecting 2025 EPS to range from $15.25 to $16.25, below the $16.33 FactSet consensus. Revenue is expected to decline by a mid-single-digit percent on a constant currency basis.

(This is a breaking news story. Check back for updates)

-Ciara Linnane

This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.

(END) Dow Jones Newswires

February 12, 2025 07:06 ET (12:06 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2510373326"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2510373326\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2510373326?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-12 20:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2510373326","market":"nz","top_or_hot":-1,"title":"Biogen's soft guidance and a decline in sales at MS portfolio weigh","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\nMW Biogen's soft guidance and a decline in sales at MS portfolio weigh\n</p>\n<p>\n     Biogen Inc.'s stock <a href=\"https://laohu8.com/S/BIIB\">$(BIIB)$</a> fell 0.6% early Wednesday, after the biotech beat fourth-quarter earnings estimates but offered guidance that lagged consensus. \n</p>\n<p>\n     Cambridge, Mass.-based Biogen had per-share earnings of $1.83 for the quarter, up from $1.71 a year ago. Adjusted for one-time items, EPS came to $3.44, ahead of the $3.35 FactSet consensus. \n</p>\n<p>\n     Revenue rose 3% to $2.455 billion and was also ahead of the $2.408 billion FactSet consensus. \n</p>\n<p>\n     Sales of the company's Alzheimer's disease treatment Leqembi came to about $87 million, ahead of the $67 million FactSet consensus. But sales of the core multiple sclerosis portfolio fell 7% to $1.070 billion. \n</p>\n<p>\n     The company is now expecting 2025 EPS to range from $15.25 to $16.25, below the $16.33 FactSet consensus. Revenue is expected to decline by a mid-single-digit percent on a constant currency basis. \n</p>\n<p>\n     (This is a breaking news story. Check back for updates) \n</p>\n<p>\n     -Ciara Linnane \n</p>\n<p>\n     This content was created by MarketWatch, which is operated by Dow Jones &amp; Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal. \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 12, 2025 07:06 ET (12:06 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biogen's soft guidance and a decline in sales at MS portfolio weigh</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiogen's soft guidance and a decline in sales at MS portfolio weigh\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-02-12 20:06</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\nMW Biogen's soft guidance and a decline in sales at MS portfolio weigh\n</p>\n<p>\n     Biogen Inc.'s stock <a href=\"https://laohu8.com/S/BIIB\">$(BIIB)$</a> fell 0.6% early Wednesday, after the biotech beat fourth-quarter earnings estimates but offered guidance that lagged consensus. \n</p>\n<p>\n     Cambridge, Mass.-based Biogen had per-share earnings of $1.83 for the quarter, up from $1.71 a year ago. Adjusted for one-time items, EPS came to $3.44, ahead of the $3.35 FactSet consensus. \n</p>\n<p>\n     Revenue rose 3% to $2.455 billion and was also ahead of the $2.408 billion FactSet consensus. \n</p>\n<p>\n     Sales of the company's Alzheimer's disease treatment Leqembi came to about $87 million, ahead of the $67 million FactSet consensus. But sales of the core multiple sclerosis portfolio fell 7% to $1.070 billion. \n</p>\n<p>\n     The company is now expecting 2025 EPS to range from $15.25 to $16.25, below the $16.33 FactSet consensus. Revenue is expected to decline by a mid-single-digit percent on a constant currency basis. \n</p>\n<p>\n     (This is a breaking news story. Check back for updates) \n</p>\n<p>\n     -Ciara Linnane \n</p>\n<p>\n     This content was created by MarketWatch, which is operated by Dow Jones &amp; Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal. \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 12, 2025 07:06 ET (12:06 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BIIB","symbol_name":"渤健公司","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2510373326","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2510373326","pubTimestamp":1739361960,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Biogen Inc.'s stock  fell 0.6% early Wednesday, after the biotech beat fourth-quarter earnings estimates but offered guidance that lagged consensus.Cambridge, Mass.-based Biogen had per-share earnings of $1.83 for the quarter, up from $1.71 a year ago. Adjusted for one-time items, EPS came to $3.44, ahead of the $3.35 FactSet consensus.Revenue rose 3% to $2.455 billion and was also ahead of the $2.408 billion FactSet consensus.Sales of the company's Alzheimer's disease treatment Leqembi came to about $87 million, ahead of the $67 million FactSet consensus. But sales of the core multiple sclerosis portfolio fell 7% to $1.070 billion.The company is now expecting 2025 EPS to range from $15.25 to $16.25, below the $16.33 FactSet consensus. Revenue is expected to decline by a mid-single-digit percent on a constant currency basis.This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Jo","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"BIIB":"渤健公司"},"translate_title":"百健(Biogen)的软指引和MS产品组合销售额下降带来压力","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BIIB":1},"content_text":"MW Biogen's soft guidance and a decline in sales at MS portfolio weigh\n\n\n     Biogen Inc.'s stock $(BIIB)$ fell 0.6% early Wednesday, after the biotech beat fourth-quarter earnings estimates but offered guidance that lagged consensus. \n\n\n     Cambridge, Mass.-based Biogen had per-share earnings of $1.83 for the quarter, up from $1.71 a year ago. Adjusted for one-time items, EPS came to $3.44, ahead of the $3.35 FactSet consensus. \n\n\n     Revenue rose 3% to $2.455 billion and was also ahead of the $2.408 billion FactSet consensus. \n\n\n     Sales of the company's Alzheimer's disease treatment Leqembi came to about $87 million, ahead of the $67 million FactSet consensus. But sales of the core multiple sclerosis portfolio fell 7% to $1.070 billion. \n\n\n     The company is now expecting 2025 EPS to range from $15.25 to $16.25, below the $16.33 FactSet consensus. Revenue is expected to decline by a mid-single-digit percent on a constant currency basis. \n\n\n     (This is a breaking news story. Check back for updates) \n\n\n     -Ciara Linnane \n\n\n     This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal. \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 12, 2025 07:06 ET (12:06 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}